Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present new data from its broad and innovative haematology portfolio at ASH 2025

Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward...
November 03, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to...
October 30, 2025 02:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche purchases shares in tender offer for 89bio, Inc

Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered...
October 29, 2025 02:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue

New dengue antigen test delivers high clinical sensitivity and specificity, as well as inclusivity for all four dengue virus serotypes, helps clinicians confidently distinguish dengue from other acute...
October 28, 2025 02:00 ET | Source: F. Hoffmann-La Roche Ltd

Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome

Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and...
October 23, 2025 01:30 ET | Source: F. Hoffmann-La Roche Ltd

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate...
October 23, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53] Roche setzt starkes Wachstum in den ersten neun Monaten 2025 fort: Verkäufe steigen um 7% (CER) – Gewinnprognose für das Gesamtjahr erhöht

Basel, 23. Oktober 2025 Konzernverkäufe stiegen in den ersten neun Monaten um 7%1 zu konstanten Wechselkursen (CER; 2% in CHF) aufgrund hoher Nachfrage nach innovativen Medikamenten und...
October 23, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Basel, 23 October 2025 Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and...
October 20, 2025 01:05 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1IMvigor011 is the first global phase III study to read out pioneering a ctDNA-...
October 20, 2025 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody...